Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.[1][2][3] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.[1] The medication was approved in the United States in 2005.[1] It is marketed widely throughout the world.[4]
See also
- Estetrol/drospirenone
- Ethinylestradiol/drospirenone
- Ethinylestradiol/drospirenone/levomefolic acid
- Ethinylestradiol/drospirenone/prasterone
- List of combined sex-hormonal preparations § Estrogens and progestogens
External links
References
- ANGELIQ (drospirenone and estradiol) Prescribing Information Bayer HealthCare Pharmaceuticals Inc., U.S. Food and Drug Administration, February 2012^
- Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals AdisInsight^
- Menopause and cardiovascular disease: the evidence Climacteric, February 2007^